21st Austria weekly - Reploid, Marinomed, CPI Europe (13/04/2026)

Reploid: Stock listed REPLOID Group AG, a company that builds and services modular and scalable insect-rearing plants, appointed Paul van der Raad as Director of Global Petfood and strenghtens its Business Development team by appointing Lars-Henrik Lau Heckmann and Maurice Brenninkmeijer. Paul van der Raad has joined the Group as Director of Global Petfood Paul van der Raad brings nearly 30 years of international experience in the pet industry. The former Global Director of Protix BV’s pet division has extensive senior leadership experience, including CEO and board-level roles in several pet food companies. With more than 12 years of experience, Lars-Henrik Lau Heckmann is a pioneer and industry leader in insect farming. For more than five of those years, he was head of business development for the renowned Big Dutchman Group, a leading systems supplier for industrial insect farms. Maurice Brenninkmeijer is a proven leader in global business development and partnerships, most recently at Protix BV, where he shaped and executed international expansion strategies, including joint ventures and strategic alliances.

CPI Europe: Real estate company CPI Europe AG has sold two retail parks, STOP SHOP San Fior and STOP SHOP Terminal Nord Udine, completing our exit from the Italian retail park market. “The transaction reflects our active portfolio management and supports our capital strategy. Proceeds will primarily reduce debt and fund investments in core markets, particularly the expansion of STOP SHOP in Central and Eastern Europe,” said Pavel Mechura, Executive Board member of CPI Europe. The Company is currently developing four retail parks in Croatia, with more planned across Serbia, Hungary and Croatia for 2027–2028.
CPI Europe AG: weekly performance: -0.13%

Marinomed: Marinomed Biotech AG has successfully completed the capital increase against cash contribution announced on March 19, 2026.  A total of 159,039 new shares of the Company were issued as part of the capital increase, with final gross proceeds of approximately EUR  2.23 million. The transaction target of gross proceeds for the Company of at least EUR 2 million was therefore even exceeded. “We are delighted with the successful capital increase. It confirms the strong confidence investors have in our company and secures the financial foundation we need to achieve our planned milestones. This financing will cover our anticipated liquidity requirements and strengthen our position in the ongoing negotiations for the marketing of our flagship products, Budesolv and Tacrosolv,” said Andreas Grassauer, CEO of Marinomed.
Marinomed Biotech: weekly performance: 6.98%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/04/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1202: ATX unverändert, der IPO-Index trudelt und ist die Addiko-Geschichte wirklich schon gegessen?

Bildnachweis

1. 21st Austria Weekly

Aktien auf dem Radar:Frequentis, Zumtobel, AT&S, Austriacard Holdings AG, Polytec Group, Rosenbauer, Verbund, OMV, voestalpine, Porr, Fabasoft, Heid AG, Reploid Group AG, Marinomed Biotech, Wolftank-Adisa, Wiener Privatbank, BKS Bank Stamm, Wolford, Amag, Bawag, EuroTeleSites AG, CPI Europe AG, Österreichische Post, Telekom Austria, UBM.

Random Partner

---

VBV
Die VBV-Gruppe ist führend bei betrieblichen Vorsorgelösungen in Österreich. Sowohl im Bereich der Firmenpensionen als auch bei der Abfertigung NEU ist die VBV Marktführer. Neben der VBV-Pensionskasse und der VBV-Vorsorgekasse gehören auch Dienstleistungsunternehmen wie die VBV-Pensionsservice-Center, die VBV-Consult, die VBV-Asset Service und die Betriebliche Altersvorsorge-SoftWare Engineering zur VBV-Gruppe.

>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner